Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysSherif Ibrahim, Martin Götte|Molecular Cancer|2017Cited by 276
Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 SignalingSherif Ibrahim, Martin Götte|PLoS ONE|2013Cited by 117
<i>HS3ST2</i> modulates breast cancer cell invasiveness via MAP kinase‐ and Tcf4 (Tcf7l2)‐dependent regulation of protease and cadherin expressionArchana Vijaya Kumar, Martin Götte|International Journal of Cancer|2014Cited by 72
Role of the Heparan Sulfate Proteoglycan Syndecan-1 (CD138) in Delayed-Type HypersensitivityBehzad Kharabi Masouleh, Martin Götte|The Journal of Immunology|2009Cited by 59
HS2ST1‐dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behaviorArchana Vijaya Kumar, Martin Götte|Cancer Science|2020Cited by 23